Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Sales Rep Survey - Part 1: Decreases in Reps Prominent in Major Firms, Is Field Force Strategy at Turning Point?
April 22, 2015
-
BUSINESS Nissan Chemical Loses Livalo Patent Suits against 8 Firms
April 21, 2015
-
BUSINESS 60% of 56 Drug Makers Increase Hiring of New Graduates in FY2015; Eisai Resumed Hiring
April 20, 2015
-
BUSINESS Takeda Hooks Up with Prof. Yamanaka on iPS Cell Research
April 17, 2015
-
REGULATORY Govt Panel to Prod Chuikyo to Revisit 14-Day Prescription Limit
April 17, 2015
-
REGULATORY Japan Faces Imperative to Increase Biostatisticians to Boost Clinical Research Quality
April 16, 2015
-
BUSINESS MSD, Astellas to Develop Januvia-Suglat Combination Drug
April 16, 2015
-
ORGANIZATION Japan Drug Costs to Remain Flat thru 2025, No Annual Price Cuts Necessary: EFPIA
April 15, 2015
-
REGULATORY Industry Won’t Grow If Pricing Premium Ended, Pharma Leaders Tell Govt
April 14, 2015
-
REGULATORY JPA’s Abe Says Link between Pricing Premium and New Drug Development Blurry
April 13, 2015
-
REGULATORY PAFSC’s Second Committee to Review PegIntron, Talion on April 24
April 13, 2015
-
BUSINESS Show Timelines for Vaccine Inclusion in Public Immunization Program: Pfizer Exec
April 10, 2015
-
BUSINESS Eli Lilly Japan Sales Cross 200 Billion Yen in 2014, Top 10 Eyed by 2020
April 9, 2015
-
BUSINESS Bayer Yakuhin Logs Double-Digit Growth for 2 Years Running on Xarelto
April 8, 2015
-
BUSINESS Drug Makers Setting Up Medical Affairs Units Independent of Sales Teams
April 7, 2015
-
ORGANIZATION JPMA to Closely Watch Clinical Research Bill to Decide Whether to Review All Ads
April 6, 2015
-
BUSINESS Sanofi Japan Sales Dip 7.6% on Generic Erosion though Plavix Grew
April 3, 2015
-
ACADEMIA Stop Use of SGLT-2 Inhibitors, NSAIDs in Elderly: Japan Geriatrics Society
April 3, 2015
-
BUSINESS Mochida Unveils New 3-Year Biz Targets, Price Revisions, Generic Penetration Weigh
April 2, 2015
-
BUSINESS Lupin Group’s Kyowa Sees Japan-India Collaboration as Key to Survival: Pres.
April 1, 2015
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…